Challenge 3: Management of malaria and the impact of interventions, prompted by Swiss Tropical and Public Health Institute and Dorian Job/Yenni Febrina.
Dr. Joseph Okebe, Merck Global Health
Joseph leads the clinical development efforts for Merck's Global Health Malaria and Schistosomiasis program. He provides strategic direction for Phase I-III clinical studies and offers scientific guidance on post-registration products. The program's portfolio includes a new malaria asset currently undergoing early clinical trials in Africa.
Ms. Katarina Zatkova, Swiss TPH
.jpg)
Katarina is an intern in a group at Swiss TPH that focuses on developing and applying statistical and mathematical methods to support National Malaria Control programs. Her work involves researching emulators and machine learning models for the calibration of OpenMalaria, live forecasting, and more.
Dr. Roberto Cittadini, CERN
Roberto earned a B.Sc. in Medical Engineering in 2017 and an M.Sc. in Biomedical Engineering and Robotics in 2020. Since 2020, he worked at CERN, focusing on contactless health monitoring using cameras, radars, and laser sensors. Roberto's research interests include worker monitoring in harsh environments, physiological signal analysis, and human-centered technologies.
Dr. Monica Golumbeanu, Swiss TPH
With an extensive, multidisciplinary background in host-pathogen genetics, computational biology, mathematical modeling, and epidemiology, Monica is passionate about understanding how infectious diseases unfold in host populations and identifying new avenues towards disease control and elimination. At Swiss TPH, her research focuses on developing data-driven computational analyses and mathematical models of malaria infection dynamics to assess the impact of interventions on host and parasite populations.
Ms. Molly Robertson, The Global Fund
Molly is a Senior Malaria Specialist at The Global Fund to Fight AIDS, Tuberculosis and Malaria as well as the co-chair of the Surveillance, Monitoring and Evaluation Working Group under the Roll Back Malaria Partnership. Molly is a global health specialist with expertise in epidemiology and anthropology and more than two decades of experience in research and evaluation of diverse global health programs.
Dr. Claude Oeuvray, Merck Global Health
Claude leads the malaria strategy and clinical phases at Merck Global Health. Previously, he worked at MMV, managing portfolios and fundraising, and co-led the development of Pyramax® through EMA submission. He has expertise in malaria drug and vaccine development, including creating the first seamless Phase IIb/III study for Coartem D at Novartis. Claude co-invented the MSP3 malaria vaccine and holds a PhD in biology from the Pasteur Institute. He also has experience in vaccines research, immunology, and innovation management.
Dr. Nathalie Gobeau, Medicines for Malaria Venture
Nathalie, PhD in Mechanical Engineering, has been leading the Pharmacometrics team at MMV since 2015. The team is using pharmacokinetics and pharmacodynamics modelling to help the development of antimalarial combination treatment from discovery to clinical development.
Dr. Dorian Job, DOK-T
Dorian is a doctor that began his professional career with MSF in 2002. From 2021 to 2023, he has become the very first General Director of the third sub-regional MSF association based in West and Central Africa, abbreviated as WaCA (for West and Central Africa).
Dr. Luigi Serio, CERN
Luigi is a Principal Investigator and Project Leader at CERN's Technology Department. He holds a MSc in Nuclear Engineering from Politecnico di Milano and a PhD from Cranfield University. With over 100 publications, Dr. Serio has expertise in nuclear and cryogenic engineering, AI, and has contributed to international projects in nuclear fusion and particle accelerators, including JET, SLAC, FERMILAB, and ITER
